Navigation Links
AdvanDx Closes $8 Million Financing Round and Elects New Board Member
Date:8/18/2009

WOBURN, Mass. and VEDBAEK, Denmark, Aug. 18 /PRNewswire/ -- AdvanDx today announced it has closed another $8 million in financing from existing stockholders, SLS Venture and LD Pensions. The additional investment is part of a series C round of financing, the first part of which was closed in September 2007, and will be used to fund the expansion of AdvanDx's molecular diagnostics product offering as well as its international sales and marketing activities.

In addition to the financing, stockholders elected Tina W. Christensen to AdvanDx board of directors. Ms. Christensen is a Vice President and CFO at the Danish health insurance company "danmark" which specializes in providing 2 million Danish citizens with supplemental health insurance to the Danish National Health Service.

"We continue to see increased adoption of our clinical diagnostic products and this latest financing will enable us to add new tests to our product portfolio and to continue to expand our customer base. We greatly appreciate our investors' strong commitment to AdvanDx and our future," said Thais T. Johansen, President and CEO of AdvanDx. "We also very much look forward to Tina W. Christensen's participation on our board of directors and the experience she brings from the health care and health insurance industry," Johansen continued.

About AdvanDx

AdvanDx is a leading provider of advanced molecular diagnostic products for the prevention, diagnosis and treatment of life-threatening, bacterial infections. AdvanDx's easy-to-use products provide fast and accurate results that enable dramatic improvements in patient care and help to save lives and reduce hospital costs.

AdvanDx's products employ standard laboratory techniques and equipment to reduce startup, implementation, technician and maintenance time, while providing fast results without sacrificing accuracy. Major medical centers, reference labs, government institutions and community hospitals throughout the United States, Europe and Asia rely on AdvanDx products as integral parts of their medical care.

For more information visit www.AdvanDx.com

About Scandinavian Life Science Venture

SLS Venture, an international venture capital company with a Scandinavian base is one of the largest in Scandinavia focusing on the life sciences sector with approximately euro 270 million under management. SLS Venture has invested in 36 pharmaceutical, medtech and biotech companies to date. Portfolio companies include Aerocrine, Exiqon, Symphogen, Light Sciences Oncology and NeuroNova.

For more information, please visit www.slsventure.com

About LD Pensions

LD Pensions is one of Denmark's largest pension funds with more than US$10 billion under management. LD Pensions has a long-term and highly selective investment strategy. Investments made in unlisted companies are based on a fundamental analysis of the opportunity with an objective to hold the investment for a minimum of 3-5 years in order to position the company for a strategic sale or stock exchange listing. It is important for LD Pensions to demonstrate a high discipline of active ownership with respect to corporate governance, information policy and the ability to meet the requirements and expectations from the surrounding society in terms of responsible environmental management and social responsibility.

For more information please visit www.ld.dk

PN1674A


'/>"/>
SOURCE AdvanDx
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AdvanDx Receives FDA 510(k) Clearance for GBS PNA FISH(R) for Rapid Detection of Group B Strep from Lim Broths
2. AdvanDx Receives FDA 510(k) Clearance for EK/P. aeruginosa PNA FISH(R)
3. HeartWare International, Inc. Closes US$60 Million Financing
4. Emdeon Closes The Sentinel Group Acquisition, Implements First Customer in Less than 30 Days
5. Croff Enterprises, Inc. Closes Merger and Will Change Name to Americas Minority Health Network, Inc.
6. Paradigm Spine Closes $21.5 Million Financing and Announces Promotion of Matt Stuttle to Position of Vice President, US Sales
7. Cardiorobotics Closes $11.6M Series A Financing to Advance Clinical Development of Snake Robot for Surgery
8. Providence Service Corporation to Report Second Quarter 2009 Results on Monday, August 10th After the Market Closes
9. SecureWorks Closes Acquisition of VeriSigns Managed Security Services Business
10. BioMed Realty Trust Closes New $18 Million Secured Loan
11. I-Therapeutix, Inc. Closes $15 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... Altima Technologies, Inc., ... network and data center assets and audio-video devices has recently updated its Visio ... shapes for free and download shapes and stencils from http://www.VisioStencils.com. , ...
(Date:3/29/2017)... Yorba Linda, Ca (PRWEB) , ... March 29, 2017 , ... ... treatment of a growing number of cancers and is touted to be the next ... of treatment, thus far, has been in the form of immune checkpoint inhibitors such ...
(Date:3/29/2017)... Richmond, VA (PRWEB) , ... March 29, 2017 , ... ... of its seventh North American office location in Richmond, Virginia, located at the Riverfront ... April 11, attended by Lieutenant Governor of Virginia Ralph S. Northam and Mayor of ...
(Date:3/28/2017)... YORK, NEW YORK (PRWEB) , ... March 28, ... ... breakthrough development, NTX Technology™, is the first technology to directly address the resolution ... Health Organization. NTX Technology™ is a patented compound of FDA and TTB approved ...
(Date:3/28/2017)... ... March 29, 2017 , ... Dr. Isabella Wentz, PharmD, FASCP, one of the ... titled The Thyroid Secret. Dr. Wentz talked about journey and research recently on a ... medication IS NOT the only solution to deal with thyroid disease. , Dr. ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017  Rosen Law Firm, ... of a class action lawsuit on behalf of purchasers ... KTOV ) pursuant and/or traceable to Kitov,s initial public ... and/or on the open market from November 20, 2015 ... Period"). The lawsuit seeks to recover damages for Kitov ...
(Date:3/28/2017)... 2017 Summary ... as a Key Component of Multichannel Marketing" provides ... landscape in the digital age. While the ... medical advancements, it has been much slower to ... on traditional channels and methods. However, the decreasing ...
(Date:3/28/2017)... -- Orexigen Therapeutics, Inc. (Nasdaq: OREX ) today ... and year ended December 31, 2016. ... Orexigen, beginning with the re-acquisition of the rights to ... team at Orexigen demonstrated remarkable focus, executing on a ... our Company while rewarding us full control of our ...
Breaking Medicine Technology: